Identification of a novel compound that suppresses breast cancer invasiveness by inhibiting transforming growth factor-β signaling via estrogen receptor α

Natsuka Goto, Hiromi Hiyoshi, Ichiaki Ito, Keisuke Iida, Yuka Nakajima, Kazuo Nagasawa, Junn Yanagisawa

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Breast cancer is the most frequently diagnosed cancer and the leading cause of death by cancer among females worldwide. An overwhelming majority of these deaths is because of metastasis. Estrogen stimulates and promotes growth of breast tumors, whereas transforming growth factor- beta (TGF-β) signaling promotes invasion and metastasis. We previously reported that estrogen and estrogen receptor alpha (ERα) suppressed breast cancer metastasis by inhibiting TGF-β signaling, whereas antiestrogens that suppress breast cancer growth, such as the selective ER modulator tamoxifen (TAM) or the pure antiestrogen fulvestrant (ICI 182,780), cannot suppress TGF-β signaling or breast cancer invasiveness. Therefore, we predicted that a compound that inhibits TGF-β signaling but does not facilitate ERα signaling would be ideal for suppressing breast cancer invasiveness and growth. In the present study, we identified an ideal candidate compound, N-23. Like estrogen, N-23 strongly decreased expression of TGF-β/Smad target gene plasminogen activator inhibitor-1 (PAI-1), but it did not increase the expression of ERα target gene pS2. While estrogen decreased the levels of phosphorylated Smad2 and Smad3, N-23 had no effect. In addition, TGF-β-dependent recruitment of Smad3 to the PAI-1 gene promoter was inhibited in the presence of estrogen or N-23. We also investigated the effects of N-23 on proliferation, migration, and invasion of breast cancer cells. In contrast to estrogen, N-23 inhibited the cellular proliferation of breast cancer cells. Moreover, we showed that N-23 suppressed the migration and invasion of breast cancer cells to the same extent as by estrogen. Taken together, our findings indicate that N-23 may be a candidate compound that is effective in inhibiting breast cancer progression.

Original languageEnglish (US)
Pages (from-to)336-343
Number of pages8
JournalJournal of Cancer
Volume5
Issue number5
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Transforming Growth Factors
Estrogen Receptors
Breast Neoplasms
Estrogens
Transforming Growth Factor beta
Estrogen Receptor alpha
Estrogen Receptor Modulators
Plasminogen Activator Inhibitor 1
Neoplasm Metastasis
Growth
Genes
Selective Estrogen Receptor Modulators
Tamoxifen
Cause of Death
Neoplasms
Cell Proliferation

Keywords

  • Breast cancer
  • Compounds
  • ERα
  • Invasion and metastasis
  • TGF-β

ASJC Scopus subject areas

  • Oncology

Cite this

Identification of a novel compound that suppresses breast cancer invasiveness by inhibiting transforming growth factor-β signaling via estrogen receptor α. / Goto, Natsuka; Hiyoshi, Hiromi; Ito, Ichiaki; Iida, Keisuke; Nakajima, Yuka; Nagasawa, Kazuo; Yanagisawa, Junn.

In: Journal of Cancer, Vol. 5, No. 5, 01.01.2014, p. 336-343.

Research output: Contribution to journalArticle

Goto, Natsuka ; Hiyoshi, Hiromi ; Ito, Ichiaki ; Iida, Keisuke ; Nakajima, Yuka ; Nagasawa, Kazuo ; Yanagisawa, Junn. / Identification of a novel compound that suppresses breast cancer invasiveness by inhibiting transforming growth factor-β signaling via estrogen receptor α. In: Journal of Cancer. 2014 ; Vol. 5, No. 5. pp. 336-343.
@article{e8b8a31a4e9242a59461d03c98cc561e,
title = "Identification of a novel compound that suppresses breast cancer invasiveness by inhibiting transforming growth factor-β signaling via estrogen receptor α",
abstract = "Breast cancer is the most frequently diagnosed cancer and the leading cause of death by cancer among females worldwide. An overwhelming majority of these deaths is because of metastasis. Estrogen stimulates and promotes growth of breast tumors, whereas transforming growth factor- beta (TGF-β) signaling promotes invasion and metastasis. We previously reported that estrogen and estrogen receptor alpha (ERα) suppressed breast cancer metastasis by inhibiting TGF-β signaling, whereas antiestrogens that suppress breast cancer growth, such as the selective ER modulator tamoxifen (TAM) or the pure antiestrogen fulvestrant (ICI 182,780), cannot suppress TGF-β signaling or breast cancer invasiveness. Therefore, we predicted that a compound that inhibits TGF-β signaling but does not facilitate ERα signaling would be ideal for suppressing breast cancer invasiveness and growth. In the present study, we identified an ideal candidate compound, N-23. Like estrogen, N-23 strongly decreased expression of TGF-β/Smad target gene plasminogen activator inhibitor-1 (PAI-1), but it did not increase the expression of ERα target gene pS2. While estrogen decreased the levels of phosphorylated Smad2 and Smad3, N-23 had no effect. In addition, TGF-β-dependent recruitment of Smad3 to the PAI-1 gene promoter was inhibited in the presence of estrogen or N-23. We also investigated the effects of N-23 on proliferation, migration, and invasion of breast cancer cells. In contrast to estrogen, N-23 inhibited the cellular proliferation of breast cancer cells. Moreover, we showed that N-23 suppressed the migration and invasion of breast cancer cells to the same extent as by estrogen. Taken together, our findings indicate that N-23 may be a candidate compound that is effective in inhibiting breast cancer progression.",
keywords = "Breast cancer, Compounds, ERα, Invasion and metastasis, TGF-β",
author = "Natsuka Goto and Hiromi Hiyoshi and Ichiaki Ito and Keisuke Iida and Yuka Nakajima and Kazuo Nagasawa and Junn Yanagisawa",
year = "2014",
month = "1",
day = "1",
doi = "10.7150/jca.7202",
language = "English (US)",
volume = "5",
pages = "336--343",
journal = "Journal of Cancer",
issn = "1837-9664",
publisher = "Ivyspring International Publisher",
number = "5",

}

TY - JOUR

T1 - Identification of a novel compound that suppresses breast cancer invasiveness by inhibiting transforming growth factor-β signaling via estrogen receptor α

AU - Goto, Natsuka

AU - Hiyoshi, Hiromi

AU - Ito, Ichiaki

AU - Iida, Keisuke

AU - Nakajima, Yuka

AU - Nagasawa, Kazuo

AU - Yanagisawa, Junn

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Breast cancer is the most frequently diagnosed cancer and the leading cause of death by cancer among females worldwide. An overwhelming majority of these deaths is because of metastasis. Estrogen stimulates and promotes growth of breast tumors, whereas transforming growth factor- beta (TGF-β) signaling promotes invasion and metastasis. We previously reported that estrogen and estrogen receptor alpha (ERα) suppressed breast cancer metastasis by inhibiting TGF-β signaling, whereas antiestrogens that suppress breast cancer growth, such as the selective ER modulator tamoxifen (TAM) or the pure antiestrogen fulvestrant (ICI 182,780), cannot suppress TGF-β signaling or breast cancer invasiveness. Therefore, we predicted that a compound that inhibits TGF-β signaling but does not facilitate ERα signaling would be ideal for suppressing breast cancer invasiveness and growth. In the present study, we identified an ideal candidate compound, N-23. Like estrogen, N-23 strongly decreased expression of TGF-β/Smad target gene plasminogen activator inhibitor-1 (PAI-1), but it did not increase the expression of ERα target gene pS2. While estrogen decreased the levels of phosphorylated Smad2 and Smad3, N-23 had no effect. In addition, TGF-β-dependent recruitment of Smad3 to the PAI-1 gene promoter was inhibited in the presence of estrogen or N-23. We also investigated the effects of N-23 on proliferation, migration, and invasion of breast cancer cells. In contrast to estrogen, N-23 inhibited the cellular proliferation of breast cancer cells. Moreover, we showed that N-23 suppressed the migration and invasion of breast cancer cells to the same extent as by estrogen. Taken together, our findings indicate that N-23 may be a candidate compound that is effective in inhibiting breast cancer progression.

AB - Breast cancer is the most frequently diagnosed cancer and the leading cause of death by cancer among females worldwide. An overwhelming majority of these deaths is because of metastasis. Estrogen stimulates and promotes growth of breast tumors, whereas transforming growth factor- beta (TGF-β) signaling promotes invasion and metastasis. We previously reported that estrogen and estrogen receptor alpha (ERα) suppressed breast cancer metastasis by inhibiting TGF-β signaling, whereas antiestrogens that suppress breast cancer growth, such as the selective ER modulator tamoxifen (TAM) or the pure antiestrogen fulvestrant (ICI 182,780), cannot suppress TGF-β signaling or breast cancer invasiveness. Therefore, we predicted that a compound that inhibits TGF-β signaling but does not facilitate ERα signaling would be ideal for suppressing breast cancer invasiveness and growth. In the present study, we identified an ideal candidate compound, N-23. Like estrogen, N-23 strongly decreased expression of TGF-β/Smad target gene plasminogen activator inhibitor-1 (PAI-1), but it did not increase the expression of ERα target gene pS2. While estrogen decreased the levels of phosphorylated Smad2 and Smad3, N-23 had no effect. In addition, TGF-β-dependent recruitment of Smad3 to the PAI-1 gene promoter was inhibited in the presence of estrogen or N-23. We also investigated the effects of N-23 on proliferation, migration, and invasion of breast cancer cells. In contrast to estrogen, N-23 inhibited the cellular proliferation of breast cancer cells. Moreover, we showed that N-23 suppressed the migration and invasion of breast cancer cells to the same extent as by estrogen. Taken together, our findings indicate that N-23 may be a candidate compound that is effective in inhibiting breast cancer progression.

KW - Breast cancer

KW - Compounds

KW - ERα

KW - Invasion and metastasis

KW - TGF-β

UR - http://www.scopus.com/inward/record.url?scp=84897015734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897015734&partnerID=8YFLogxK

U2 - 10.7150/jca.7202

DO - 10.7150/jca.7202

M3 - Article

VL - 5

SP - 336

EP - 343

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 5

ER -